HR-positive, HER2-negative early invasive breast cancer
Conditions
Interventions
Group of Patients with HR+/HER2- Early Breast Cancer:None
Sponsors
Ningbo Medical Centre Lihuili Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Patients pathologically diagnosed with HR+/HER2- early breast cancer; 2.Aged >= 18 years old, with clear consciousness and normal verbal communication ability, capable of independently understanding and completing the questionnaire; 3.Have received or plan to receive adjuvant endocrine therapy combined with CDK4/6 inhibitors; 4.Voluntarily participate in this study and sign the written informed consent form; 5.Be willing to cooperate to finish all questionnaire items.
Exclusion criteria
Exclusion criteria: 1.Patients with distant metastasis or recurrent metastatic breast cancer; 2.Subjects with cognitive, hearing or language disorders who are unable to complete the questionnaire independently; 3.Other conditions judged by researchers to be ineligible for participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Preference weight of each attribute of CDK4/6 inhibitor combined adjuvant therapy; | — |
Countries
China
Contacts
Public ContactJinhua Ding
Ningbo Medical Centre Lihuili Hospital
Outcome results
None listed